Natac closes 2024 with record sales of nearly 36 million euros
The company increased its normalized EBITDA by 47%, reaching €13.82 million.
Natac Group (NAT), a biotechnology company specialized in the sustainable production of botanical extracts and omega-3 oils with proven health benefits, closed 2024 with record sales and EBITDA, further consolidating its position as one of the leaders in the natural and healthy ingredients industry.
Specifically, the group’s revenue reached €35.85 million, representing a 35% increase over the previous year. Meanwhile, normalized EBITDA reached €13.82 million, up 47% from the prior year.
Strong performance across all business segments drove revenue and EBITDA growth, with a notable highlight being the animal nutrition division, which grew by 121% in 2024. Additionally, operational optimization and acquiring more than 80 new clients from strategic markets such as Italy, France, Germany, and Spain contributed significantly to these results.
The main milestones for 2024 include obtaining the GMP quality certification that allows the company to manufacture APIS for the pharmaceutical sector and the start-up of the Omega 3 factory in As Somozas, the largest in Spain.
The company expects to close 2025 with revenues of over 55 million euros and a normalized EBITDA of over 20 million euros, while the guidance for 2026 calls for revenues and a normalized EBITDA of over 68 million euros and 26 million euros, respectively.